Shares of Origin Enterprises plc (LON:OGN – Get Free Report) hit a new 52-week high on Tuesday following a dividend announcement from the company. The stock traded as high as GBX 3.60 ($0.05) and last traded at GBX 3.52 ($0.05), with a volume of 5500 shares. The stock had previously closed at GBX 3.45 ($0.05).
The newly announced dividend which will be paid on Friday, February 14th. Investors of record on Thursday, January 23rd will be given a dividend of €0.14 ($0.15) per share. This is a positive change from Origin Enterprises’s previous dividend of $0.03. This represents a yield of 3.96%. The ex-dividend date is Thursday, January 23rd. Origin Enterprises’s dividend payout ratio (DPR) is currently 3,953.49%.
Analysts Set New Price Targets
Separately, Shore Capital reissued a “buy” rating on shares of Origin Enterprises in a research report on Tuesday.
Origin Enterprises Price Performance
The firm has a market cap of £3.73 million, a price-to-earnings ratio of 8.19 and a beta of 0.72. The company has a debt-to-equity ratio of 94.70, a quick ratio of 0.69 and a current ratio of 1.42. The business has a 50 day simple moving average of GBX 3.20 and a 200-day simple moving average of GBX 3.17.
Origin Enterprises Company Profile
Origin Enterprises plc provides agronomy services company in Ireland, the United Kingdom, Belgium, Brazil, Poland, Romania, Ukraine, and Latin America. It develops products and services to improve soil fertility, nutrient use efficiency, and crop productivity. The company provides integrated agronomy and on-farm services comprising agronomy advice, services, and inputs directly to arable, fruit, and vegetable growers; and seed, nutrients, crop protection products and digital tools.
Read More
- Five stocks we like better than Origin Enterprises
- Pros And Cons Of Monthly Dividend Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Health Care Stocks Explained: Why You Might Want to Invest
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Origin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Origin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.